T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Wins FDA Clearance for a Second Phase 2 Study
T-MAXIMUM has received FDA clearance for a Phase 2 study of MT027, its B7-H3-targeted universal CAR-T therapy, in brain metastases. It follows an earlier clearance for the same product in recurrent glioblastoma.